| Androgen receptor signaling in prostate cancer Z Culig, FR Santer Cancer and Metastasis Reviews 33, 413-427, 2014 | 332 | 2014 |
| Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines FR Santer, PPS Höschele, SJ Oh, HHH Erb, J Bouchal, IT Cavarretta, ... Molecular cancer therapeutics 10 (9), 1644-1655, 2011 | 255 | 2011 |
| Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells FR Santer, K Malinowska, Z Culig, IT Cavarretta Endocrine-related cancer 17 (1), 241, 2010 | 168 | 2010 |
| Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways M Puhr, FR Santer, H Neuwirt, M Susani, JA Nemeth, A Hobisch, ... Cancer research 69 (18), 7375-7384, 2009 | 104 | 2009 |
| The immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signalling G Nappo, F Handle, FR Santer, RV McNeill, RI Seed, AT Collins, ... Oncogenesis 6 (5), e342-e342, 2017 | 99 | 2017 |
| Movember GAP1 PDX project: an international collection of serially transplantable prostate cancer patient‐derived xenograft (PDX) models NM Navone, WM van Weerden, RL Vessella, ED Williams, Y Wang, ... The Prostate 78 (16), 1262-1282, 2018 | 97 | 2018 |
| Nuclear insulin-like growth factor binding protein-3 induces apoptosis and is targeted to ubiquitin/proteasome–dependent proteolysis FR Santer, N Bacher, B Moser, D Morandell, S Ressler, SM Firth, ... Cancer research 66 (6), 3024-3033, 2006 | 91 | 2006 |
| Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent … H Neuwirt, M Puhr, FR Santer, M Susani, W Doppler, G Marcias, V Rauch, ... The American journal of pathology 174 (5), 1921-1930, 2009 | 85 | 2009 |
| Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways SJ Oh, HHH Erb, A Hobisch, FR Santer, Z Culig Endocrine-related cancer 19 (3), 305, 2012 | 75 | 2012 |
| Therapy escape mechanisms in the malignant prostate FR Santer, HHH Erb, RV McNeill Seminars in cancer biology 35, 133-144, 2015 | 72 | 2015 |
| High-risk human papillomavirus E7 oncoprotein detection in cervical squamous cell carcinoma S Ressler, R Scheiden, K Dreier, A Laich, E Müller-Holzner, H Pircher, ... Clinical cancer research 13 (23), 7067-7072, 2007 | 67 | 2007 |
| IL6 sensitizes prostate cancer to the antiproliferative effect of IFNα2 through IRF9 HHH Erb, RV Langlechner, PL Moser, F Handle, T Casneuf, K Verstraeten, ... Endocrine-related cancer 20 (5), 677, 2013 | 65 | 2013 |
| Transcriptional coactivators p300 and CBP stimulate estrogen receptor‐beta signaling and regulate cellular events in prostate cancer J Bouchal, FR Santer, PPS Höschele, E Tomastikova, H Neuwirt, Z Culig The Prostate 71 (4), 431-437, 2011 | 61 | 2011 |
| Androgen receptor co-activators in the regulation of cellular events in prostate cancer Z Culig, FR Santer World journal of urology 30, 297-302, 2012 | 56 | 2012 |
| DNA damage signalling barrier, oxidative stress and treatment-relevant DNA repair factor alterations during progression of human prostate cancer D Kurfurstova, J Bartkova, R Vrtel, A Mickova, A Burdova, D Majera, ... Molecular oncology 10 (6), 879-894, 2016 | 54 | 2016 |
| SOCS-3 antagonises the proliferative and migratory effects of fibroblast growth factor-2 in prostate cancer by inhibition of p44/p42 MAPK signalling M Puhr, FR Santer, H Neuwirt, G Marcias, A Hobisch, Z Culig Endocrine-Related Cancer 17 (2), 525-538, 2010 | 53 | 2010 |
| Oncolytic activity of the rhabdovirus VSV‐GP against prostate cancer C Urbiola, FR Santer, M Petersson, G van der Pluijm, W Horninger, ... International journal of cancer 143 (7), 1786-1796, 2018 | 46 | 2018 |
| SOCS3 modulates the response to enzalutamide and is regulated by androgen receptor signaling and CpG methylation in prostate cancer cells F Handle, HHH Erb, B Luef, J Hoefer, D Dietrich, W Parson, G Kristiansen, ... Molecular Cancer Research 14 (6), 574-585, 2016 | 45 | 2016 |
| The STAT3 inhibitor galiellalactone reduces IL6-mediated AR activity in benign and malignant prostate models F Handle, M Puhr, G Schaefer, N Lorito, J Hoefer, M Gruber, ... Molecular cancer therapeutics 17 (12), 2722-2731, 2018 | 43 | 2018 |
| Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy FR Santer, HHH Erb, SJ Oh, F Handle, GE Feiersinger, B Luef, H Bu, ... Oncotarget 6 (8), 6105, 2015 | 35 | 2015 |
